Debate over RNA Transcription

Researchers question earlier findings of a new mechanism for gene regulation.

| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

FLICKR, KYZ

Results regarding a new type of RNA editing, reported last July by Vivian Cheung at the University of Pennsylvania, were questioned last Thursday (March 15) by three groups publishing technical commentaries in Science.

Cheung’s research found more than 10,000 cases in which RNA underwent an additional editing step before being translated into protein, suggesting a possible rewrite of the central dogma, which states that the RNA message usually matches the original gene. The work was immediately criticized by biologists who questioned Cheung’s interpretation of her results.

Now, three independent research groups who reanalyzed Cheung’s data say that up to 94 percent of the reported RNA editing sites were inaccurately assessed. They state that errors in sequencing, gene mapping, and genotyping, among others, led to an ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Keywords

Meet the Author

  • Edyta Zielinska

    This person does not yet have a bio.
Share
TS Digest January 2025
January 2025, Issue 1

Why Do Some People Get Drunk Faster Than Others?

Genetics and tolerance shake up how alcohol affects each person, creating a unique cocktail of experiences.

View this Issue
Sex Differences in Neurological Research

Sex Differences in Neurological Research

bit.bio logo
New Frontiers in Vaccine Development

New Frontiers in Vaccine Development

Sino
New Approaches for Decoding Cancer at the Single-Cell Level

New Approaches for Decoding Cancer at the Single-Cell Level

Biotium logo
Learn How 3D Cell Cultures Advance Tissue Regeneration

Organoids as a Tool for Tissue Regeneration Research 

Acro 

Products

Artificial Inc. Logo

Artificial Inc. proof-of-concept data demonstrates platform capabilities with NVIDIA’s BioNeMo

Sapient Logo

Sapient Partners with Alamar Biosciences to Extend Targeted Proteomics Services Using NULISA™ Assays for Cytokines, Chemokines, and Inflammatory Mediators

Bio-Rad Logo

Bio-Rad Extends Range of Vericheck ddPCR Empty-Full Capsid Kits to Optimize AAV Vector Characterization

Scientist holding a blood sample tube labeled Mycoplasma test in front of many other tubes containing patient samples

Accelerating Mycoplasma Testing for Targeted Therapy Development